

Guanzhang Li

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2563873/publications.pdf>

Version: 2024-02-01

54
papers

2,139
citations

430874

18
h-index

265206

42
g-index

56
all docs

56
docs citations

56
times ranked

2014
citing authors

#	ARTICLE	IF	CITATIONS
1	Chinese Glioma Genome Atlas (CGGA): A Comprehensive Resource with Functional Genomic Data from Chinese Glioma Patients. <i>Genomics, Proteomics and Bioinformatics</i> , 2021, 19, 1-12.	6.9	439
2	Tumor Purity as an Underlying Key Factor in Glioma. <i>Clinical Cancer Research</i> , 2017, 23, 6279-6291.	7.0	372
3	Clinical practice guidelines for the management of adult diffuse gliomas. <i>Cancer Letters</i> , 2021, 499, 60-72.	7.2	194
4	Molecular and clinical characterization of PD-L1 expression at transcriptional level via 976 samples of brain glioma. <i>Oncolmmunology</i> , 2016, 5, e1196310.	4.6	176
5	Molecular and clinical characterization of TIM-3 in glioma through 1,024 samples. <i>Oncolmmunology</i> , 2017, 6, e1328339.	4.6	114
6	An MRI radiomics approach to predict survival and tumour-infiltrating macrophages in gliomas. <i>Brain</i> , 2022, 145, 1151-1161.	7.6	75
7	Genetic and clinical characterization of B7 β (CD276) expression and epigenetic regulation in diffuse brain glioma. <i>Cancer Science</i> , 2018, 109, 2697-2705.	3.9	73
8	Detection of ATRX and IDH1-R132H immunohistochemistry in the progression of 211 paired gliomas. <i>Oncotarget</i> , 2016, 7, 16384-16395.	1.8	53
9	ATRX, IDH1-R132H and Ki-67 immunohistochemistry as a classification scheme for astrocytic tumors. <i>Oncoscience</i> , 2016, 3, 258-265.	2.2	42
10	ALDH1A3 induces mesenchymal differentiation and serves as a predictor for survival in glioblastoma. <i>Cell Death and Disease</i> , 2018, 9, 1190.	6.3	42
11	A novel gene signature based on five glioblastoma stem-like cell relevant genes predicts the survival of primary glioblastoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 439-447.	2.5	36
12	Expression profile analysis of antisense long non-coding RNA identifies WDFY3-AS2 as a prognostic biomarker in diffuse glioma. <i>Cancer Cell International</i> , 2018, 18, 107.	4.1	33
13	Predictive value of MGMT promoter methylation on the survival of TMZ treated <i>IDH</i>-mutant glioblastoma. <i>Cancer Biology and Medicine</i> , 2021, 18, 271-282.	3.0	31
14	EFEMP2 indicates assembly of M0 macrophage and more malignant phenotypes of glioma. <i>Aging</i> , 2020, 12, 8397-8412.	3.1	30
15	Clinical characterization and immunosuppressive regulation of CD161 (KLRB1) in glioma through 916 samples. <i>Cancer Science</i> , 2022, 113, 756-769.	3.9	29
16	Identification of an ATP metabolism-related signature associated with prognosis and immune microenvironment in gliomas. <i>Cancer Science</i> , 2020, 111, 2325-2335.	3.9	27
17	Single-Cell RNA-Sequencing Shift in the Interaction Pattern Between Glioma Stem Cells and Immune Cells During Tumorigenesis. <i>Frontiers in Immunology</i> , 2020, 11, 581209.	4.8	26
18	CKAP2 expression is associated with glioma tumor growth and acts as a prognostic factor in high-grade glioma. <i>Oncology Reports</i> , 2018, 40, 2036-2046.	2.6	25

#	ARTICLE	IF	CITATIONS
19	RGS16 promotes glioma progression and serves as a prognostic factor. <i>CNS Neuroscience and Therapeutics</i> , 2020, 26, 791-803.	3.9	24
20	Plasminogen Activator Urokinase Receptor Implies Immunosuppressive Features and Acts as an Unfavorable Prognostic Biomarker in Glioma. <i>Oncologist</i> , 2021, 26, e1460-e1469.	3.7	21
21	RNA processing genes characterize RNA splicing and further stratify lower-grade glioma. <i>JCI Insight</i> , 2019, 5, .	5.0	20
22	Redox Regulator GLRX Is Associated With Tumor Immunity in Glioma. <i>Frontiers in Immunology</i> , 2020, 11, 580934.	4.8	17
23	Comprehensive Analysis of the Clinical and Biological Significances of Endoplasmic Reticulum Stress in Diffuse Gliomas. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 619396.	3.7	16
24	A computational guided, functional validation of a novel therapeutic antibody proposes Notch signaling as a clinical relevant and druggable target in glioma. <i>Scientific Reports</i> , 2020, 10, 16218.	3.3	15
25	Glioma-related epilepsy in patients with diffuse high-grade glioma after the 2016 WHO update: seizure characteristics, risk factors, and clinical outcomes. <i>Journal of Neurosurgery</i> , 2022, 136, 67-75.	1.6	15
26	ABCC8 mRNA expression is an independent prognostic factor for glioma and can predict chemosensitivity. <i>Scientific Reports</i> , 2020, 10, 12682.	3.3	14
27	The Landscape of Viral Expression Reveals Clinically Relevant Viruses with Potential Capability of Promoting Malignancy in Lower-Grade Glioma. <i>Clinical Cancer Research</i> , 2017, 23, 2177-2185.	7.0	12
28	Carbonic Anhydrase XII is a Clinically Significant, Molecular Tumor-Subtype Specific Therapeutic Target in Glioma with the Potential to Combat Invasion of Brain Tumor Cells. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 1707-1718.	2.0	12
29	Association of high-dose radiotherapy with improved survival in patients with newly diagnosed low-grade gliomas. <i>Cancer</i> , 2022, 128, 1085-1092.	4.1	12
30	In Vitro Validation of the Therapeutic Potential of Dendrimer-Based Nanoformulations against Tumor Stem Cells. <i>International Journal of Molecular Sciences</i> , 2022, 23, 5691.	4.1	11
31	FGFR3, as a receptor tyrosine kinase, is associated with differentiated biological functions and improved survival of glioma patients. <i>Oncotarget</i> , 2016, 7, 84587-84593.	1.8	10
32	Postoperative standard chemoradiotherapy benefits primary glioblastoma patients of all ages. <i>Cancer Medicine</i> , 2020, 9, 1955-1965.	2.8	10
33	NK Cell-Based Immunotherapy and Therapeutic Perspective in Gliomas. <i>Frontiers in Oncology</i> , 2021, 11, 751183.	2.8	10
34	MEGF10, a Glioma Survival-Associated Molecular Signature, Predicts IDH Mutation Status. <i>Disease Markers</i> , 2018, 2018, 1-8.	1.3	9
35	Identification of IDH-mutant gliomas by a prognostic signature according to gene expression profiling. <i>Aging</i> , 2018, 10, 1977-1988.	3.1	8
36	RPP30, a transcriptional regulator, is a potential pathogenic factor in glioblastoma. <i>Aging</i> , 2020, 12, 16155-16171.	3.1	8

#	ARTICLE	IF	CITATIONS
37	A new glioma grading model based on histopathology and Bone Morphogenetic Protein 2 mRNA expression. <i>Scientific Reports</i> , 2020, 10, 18420.	3.3	7
38	A novel DNA repair-related nomogram predicts survival in low-grade gliomas. <i>CNS Neuroscience and Therapeutics</i> , 2021, 27, 186-195.	3.9	7
39	High-sensitive clinical diagnostic method for PTPRZ1-MET and the characteristic protein structure contributing to ligand-independent MET activation. <i>CNS Neuroscience and Therapeutics</i> , 2021, 27, 617-628.	3.9	7
40	Molecular Characterization and Clinical Relevance of ANXA1 in Gliomas via 1,018 Chinese Cohort Patients. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 777182.	3.7	6
41	Galectin-9/TIM-3 as a Key Regulator of Immune Response in Gliomas With Chromosome 1p/19q Codeletion. <i>Frontiers in Immunology</i> , 2021, 12, 800928.	4.8	6
42	Transcriptomic Profiling Identifies a DNA Repair-Related Signature as a Novel Prognostic Marker in Lower Grade Gliomas. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 2079-2086.	2.5	5
43	A novel methylation signature predicts radiotherapy sensitivity in glioma. <i>Scientific Reports</i> , 2020, 10, 20406.	3.3	5
44	Comparative profiling of immune genes improves the prognoses of lower grade gliomas. <i>Cancer Biology and Medicine</i> , 2021, 18, 0-0.	3.0	5
45	Long-term efficacy of surgical resection with or without adjuvant therapy for treatment of secondary glioblastoma in adults. <i>Neuro-Oncology Advances</i> , 2020, 2, vdaa098.	0.7	4
46	High-dose radiation associated with improved survival in IDH-wildtype low-grade glioma. <i>Chinese Neurosurgical Journal</i> , 2021, 7, 22.	0.9	3
47	New-Onset Postoperative Seizures in Patients With Diffuse Gliomas: A Risk Assessment Analysis. <i>Frontiers in Neurology</i> , 2021, 12, 682535.	2.4	3
48	FXYD2 mRNA expression represents a new independent factor that affects survival of glioma patients and predicts chemosensitivity of patients to temozolomide. <i>BMC Neurology</i> , 2021, 21, 438.	1.8	2
49	Progenitor cells derived from gene-engineered human induced pluripotent stem cells as synthetic cancer cell alternatives for in vitro pharmacology. <i>Biotechnology Journal</i> , 2022, , 2100693.	3.5	2
50	Canonical WNT pathway inhibition reduces ATP synthesis rates in glioblastoma stem cells. <i>Frontiers in Bioscience</i> , 2022, 27, 1.	2.1	1
51	Functional clustering analysis identifies specific subtypes of aldehyde dehydrogenase associated with glioma immunity. <i>Translational Cancer Research</i> , 2021, 10, 5052-5064.	1.0	1
52	Uronic acid metabolic process-related gene expression-based signature predicts overall survival of glioma. <i>Bioscience Reports</i> , 2021, 41, .	2.4	0
53	A novel gene signature based on five immune checkpoint genes predicts the survival of glioma. <i>Chinese Neurosurgical Journal</i> , 2021, 7, 15.	0.9	0
54	Multomics Analysis Reveals the Prognostic Non-tumor Cell Landscape in Glioblastoma Niches. <i>Frontiers in Genetics</i> , 2021, 12, 741325.	2.3	0